• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Integrated analysis and regulation of cellular diversity for disease treatment

Planned Research

Project AreaIntegrated analysis and regulation of cellular diversity
Project/Area Number 17H06327
Research Category

Grant-in-Aid for Scientific Research on Innovative Areas (Research in a proposed research area)

Allocation TypeSingle-year Grants
Review Section Complex systems
Research InstitutionJapanese Foundation for Cancer Research

Principal Investigator

FUJITA Naoya  公益財団法人がん研究会, がん化学療法センター, 所長 (20280951)

Co-Investigator(Kenkyū-buntansha) 高木 聡  公益財団法人がん研究会, がん化学療法センター 基礎研究部, 研究員 (20582240)
田崎 創平  北海道大学, 理学研究院, 准教授 (50713020)
竹本 愛  公益財団法人がん研究会, がん化学療法センター 基礎研究部, 研究員 (20706494)
片山 量平  公益財団法人がん研究会, がん化学療法センター 基礎研究部, 部長 (60435542)
Project Period (FY) 2017-06-30 – 2022-03-31
Project Status Completed (Fiscal Year 2021)
Budget Amount *help
¥308,620,000 (Direct Cost: ¥237,400,000、Indirect Cost: ¥71,220,000)
Fiscal Year 2021: ¥58,500,000 (Direct Cost: ¥45,000,000、Indirect Cost: ¥13,500,000)
Fiscal Year 2020: ¥58,500,000 (Direct Cost: ¥45,000,000、Indirect Cost: ¥13,500,000)
Fiscal Year 2019: ¥58,500,000 (Direct Cost: ¥45,000,000、Indirect Cost: ¥13,500,000)
Fiscal Year 2018: ¥58,500,000 (Direct Cost: ¥45,000,000、Indirect Cost: ¥13,500,000)
Fiscal Year 2017: ¥74,620,000 (Direct Cost: ¥57,400,000、Indirect Cost: ¥17,220,000)
Keywords癌 / 細胞・組織 / 遺伝子 / 計算機科学 / 数理科学 / 臨床 / 数理モデル / 再生医療
Outline of Final Research Achievements

In this research project, we aimed to analyze the molecular mechanisms of heterogenous multicellular interaction and organ maintenance, and to develop new molecular-targeting drugs for diseases caused by abnormal cellular interactions. In osteosarcoma, we discovered that interaction with platelets promotes its tumor growth and metastasis, and found a drug to overcome it. From single-cell analysis of patient-derived lung tumors harboring treatment-resistant phenotype, we revealed the existence of drug-resistant persister cells in the therapeutic drug-treated tumors. We also found new resistance mechanisms against cancer immunotherapy. In the system of angiogenesis, we constructed a mathematical model that can simultaneously analyze cell-level phenomena and macrovascular network formation from a mathematical model of the vascular endothelial cell motion and the phase fields of surrounding microenvironment and vascular morphology.

Academic Significance and Societal Importance of the Research Achievements

腫瘍組織を1つの臓器と見立て、腫瘍を構成するがん細胞と間質細胞や免疫細胞や血小板との相互作用に着目することで、細胞社会ダイバーシティーの成り立ちを明らかにした。1細胞レベルでの解析を行う手法を確立するとともに、様々な新規治療標的及び新規治療法の発見に貢献した。これら研究成果は、治療薬耐性化の分子機構の発見という学術的意義にとどまらず、新たながん治療薬候補の提示といったがん医療への貢献という意味で社会的意義も極めて高い結果となっている。また、薬剤耐性とその克服に量子化学計算を取り入れることができることも証明することができ、計算機科学と薬学の融合といった新興領域創成への貢献も果たした。

Report

(6 results)
  • 2021 Annual Research Report   Final Research Report ( PDF )
  • 2020 Annual Research Report
  • 2019 Annual Research Report
  • 2018 Annual Research Report
  • 2017 Annual Research Report
  • Research Products

    (89 results)

All 2022 2021 2020 2019 2018 2017 Other

All Int'l Joint Research (3 results) Journal Article (26 results) (of which Int'l Joint Research: 8 results,  Peer Reviewed: 25 results,  Open Access: 23 results,  Acknowledgement Compliant: 1 results) Presentation (47 results) (of which Int'l Joint Research: 7 results,  Invited: 11 results) Book (1 results) Remarks (12 results)

  • [Int'l Joint Research] Universite Paris Saclay(フランス)

    • Related Report
      2020 Annual Research Report
  • [Int'l Joint Research] ETH Zurich(スイス)

    • Related Report
      2020 Annual Research Report
  • [Int'l Joint Research] Universite´ Paris Saclay(フランス)

    • Related Report
      2019 Annual Research Report
  • [Journal Article] Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation2022

    • Author(s)
      Sagawa Ray、Sakata Seiji、Gong Bo、Seto Yosuke、Takemoto Ai、Takagi Satoshi、Ninomiya Hironori、Yanagitani Noriko、Nakao Masayuki、Mun Mingyon、Uchibori Ken、Nishio Makoto、Miyazaki Yasunari、Shiraishi Yuichi、Ogawa Seishi、Kataoka Keisuke、Fujita Naoya、Takeuchi Kengo、Katayama Ryohei
    • Journal Title

      JCI Insight

      Volume: 7 Issue: 1 Pages: 1-19

    • DOI

      10.1172/jci.insight.153323

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer2022

    • Author(s)
      Shimizu Yuki、Okada Koutaroh、Adachi Jun、Abe Yuichi、Narumi Ryohei、Uchibori Ken、Yanagitani Noriko、Koike Sumie、Takagi Satoshi、Nishio Makoto、Fujita Naoya、Katayama Ryohei
    • Journal Title

      npj Precision Oncology

      Volume: 6 Issue: 1 Pages: 16-16

    • DOI

      10.1038/s41698-022-00260-0

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Multicellular model of angiogenesis2022

    • Author(s)
      Nakazawa Takashi、Tasaki Sohei、Nakai Kiyohiko、Suzuki Takashi
    • Journal Title

      AIMS Bioengineering

      Volume: 9 Issue: 1 Pages: 44-60

    • DOI

      10.3934/bioeng.2022004

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Platelet-derived lysophosphatidic acid mediated LPAR1 activation as a therapeutic target for osteosarcoma metastasis2021

    • Author(s)
      Takagi Satoshi、Sasaki Yuki、Koike Sumie、Takemoto Ai、Seto Yosuke、Haraguchi Mizuki、Ukaji Takao、Kawaguchi Tokuichi、Sugawara Minoru、Saito Masanori、Funauchi Yuki、Ae Keisuke、Matsumoto Seiichi、Fujita Naoya、Katayama Ryohei
    • Journal Title

      Oncogene

      Volume: 40 Issue: 36 Pages: 5548-5558

    • DOI

      10.1038/s41388-021-01956-6

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Novel knock-in mouse model for the evaluation of the therapeutic efficacy and toxicity of human podoplanin-targeting agents.2021

    • Author(s)
      Ukaji T, Takemoto A, Shibata H, Kakino M, Takagi S, Katayama R, Fujita N
    • Journal Title

      Cancer Science

      Volume: In press Issue: 6 Pages: 2299-2313

    • DOI

      10.1111/cas.14891

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity2021

    • Author(s)
      Yoshizawa Takahiro、Uchibori Ken、Araki Mitsugu、Matsumoto Shigeyuki、Ma Biao、Kanada Ryo、Seto Yosuke、Oh-hara Tomoko、Koike Sumie、Ariyasu Ryo、Kitazono Satoru、Ninomiya Hironori、Takeuchi Kengo、Yanagitani Noriko、Takagi Satoshi、Kishi Kazuma、Fujita Naoya、Okuno Yasushi、Nishio Makoto、Katayama Ryohei
    • Journal Title

      npj Precision Oncology

      Volume: 5 Issue: 1 Pages: 32-32

    • DOI

      10.1038/s41698-021-00170-7

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Monitoring epidermal growth factor receptor C797S mutation in Japanese non?small cell lung cancer patients with serial cell‐free DNA evaluation using digital droplet PCR2021

    • Author(s)
      Ariyasu Ryo、Uchibori Ken、Sasaki Takaaki、Tsukahara Mika、Kiyotani Kazuma、Yoshida Ryohei、Ono Yusuke、Kitazono Satoru、Ninomiya Hironori、Ishikawa Yuichi、Mizukami Yusuke、Yanagitani Noriko、Fujita Naoya、Nishio Makoto、Katayama Ryohei
    • Journal Title

      Cancer Science

      Volume: - Issue: 6 Pages: 2371-2380

    • DOI

      10.1111/cas.14879

    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Time Changes in the VEGF-A Concentration Gradient Lead Neovasculature to Engage in Stair-Like Growth2021

    • Author(s)
      Ito Yukinobu、Minerva Dhisa、Tasaki Sohei、Yoshida Makoto、Suzuki Takashi、Goto Akiteru
    • Journal Title

      Springer Proceedings in Mathematics & Statistics

      Volume: 370 Pages: 226-234

    • DOI

      10.1007/978-981-16-4866-3_15

    • ISBN
      9789811648656, 9789811648663
    • Related Report
      2021 Annual Research Report
    • Peer Reviewed / Int'l Joint Research
  • [Journal Article] Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer2021

    • Author(s)
      Mizuta Hayato、Okada Koutaroh、Araki Mitsugu、Adachi Jun、Takemoto Ai、Kutkowska Justyna、Maruyama Kohei、Friboulet Luc、Katayama Kazuhiro、Ma Biao、Sasakura Yoko、Sagae Yukari、Kukimoto-Niino Mutsuko、Shirouzu Mikako、Takagi Satoshi、Simizu Siro、Nishio Makoto、Okuno Yasushi、Fujita Naoya、Katayama Ryohei, et al
    • Journal Title

      Nature Communications

      Volume: 12 Issue: 1 Pages: 1261-1261

    • DOI

      10.1038/s41467-021-21396-w

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Cryo-EM structures reveal distinct mechanisms of inhibition of the human multidrug transporter ABCB12020

    • Author(s)
      Nosol Kamil、Romane Ksenija、Irobalieva Rossitza N.、Alam Amer、Kowal Julia、Fujita Naoya、Locher Kaspar P.
    • Journal Title

      Proceedings of the National Academy of Sciences

      Volume: 117 Issue: 42 Pages: 26245-26253

    • DOI

      10.1073/pnas.2010264117

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Efficacy of EGFR tyrosine kinase inhibitors in patients having EGFR-activating mutations with or without BIM polymorphisms2020

    • Author(s)
      Ariyasu Ryo、Yanagitani Noriko、Tadokoro Kenichi、Yamaguchi Toshikazu、Uchibori Ken、Kitazono Satoru、Fujita Naoya、Katayama Ryohei、Nishio Makoto
    • Journal Title

      Cancer Chemotherapy and Pharmacology

      Volume: 86 Issue: 4 Pages: 517-525

    • DOI

      10.1007/s00280-020-04136-7

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non?small cell lung cancer and the clinical responses based on the resistant mechanisms2020

    • Author(s)
      Yanagitani N、Uchibori K、Koike S、Tsukahara、Kitazono、Yoshizawa、Horiike、Ohyanagi、Tambo、Nishikawa、Fujita、Katayama、Nishio M.
    • Journal Title

      Cancer Science

      Volume: 111 Issue: 3 Pages: 932-939

    • DOI

      10.1111/cas.14314

    • Related Report
      2020 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer2019

    • Author(s)
      Gong Bo, Kiyotani Kazuma, Sakata Seiji, Nagano Seiji, Kumehara Shun, Baba Satoko, Besse Benjamin, Yanagitani Noriko, Friboulet Luc, Nishio Makoto, Takeuchi Kengo, Kawamoto Hiroshi, Fujita Naoya, Katayama Ryohei
    • Journal Title

      The Journal of Experimental Medicine

      Volume: 216 Issue: 4 Pages: 982-1000

    • DOI

      10.1084/jem.20180870

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models2019

    • Author(s)
      Katayama R、Bo G、Togashi N、Miyamoto M、Kiga M、Iwasaki S、Kamai Y、Tominaga Y、Takeda Y、Kagoshima Y、Shimizu Y、Seto Y、Oh-hara T、Koike S、Nakao N、Hanzawa H、Watanabe K、Yoda S、Yanagitani N、Hata AN.、Shaw AT、Nishio M、Fujita N、Isoyama T.
    • Journal Title

      Nature Communications

      Volume: 10 Issue: 1 Pages: 3604-3604

    • DOI

      10.1038/s41467-019-11496-z

    • Related Report
      2019 Annual Research Report
    • Peer Reviewed / Open Access / Int'l Joint Research
  • [Journal Article] Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance2019

    • Author(s)
      Okada Koutaroh、Araki Mitsugu、Sakashita Takuya、Ma Biao、Kanada Ryo、Yanagitani Noriko、Horiike Atsushi、Koike Sumie、Oh-hara Tomoko、Watanabe Kana、Tamai Keiichi、Maemondo Makoto、Nishio Makoto、Ishikawa Takeshi、Okuno Yasushi、Fujita Naoya、Katayama Ryohei
    • Journal Title

      EBioMedicine

      Volume: 41 Pages: 105-119

    • DOI

      10.1016/j.ebiom.2019.01.019

    • NAID

      120006892063

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Identification of mutation accumulation as resistance mechanism emerging in first-line osimertinib treatment.2018

    • Author(s)
      Ken Uchibori, Naohiko Inase, Makoto Nishio, Naoya Fujita, Ryohei Katayama
    • Journal Title

      J. Thorac. Oncol.

      Volume: 13 Issue: 7 Pages: 915-925

    • DOI

      10.1016/j.jtho.2018.04.005

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] High ratio of T790M to EGFR activating mutations correlate with the osimertinib response in non-small-cell lung cancer2018

    • Author(s)
      Ariyasu Ryo、Nishikawa Shingo、Uchibori Ken、Oh-hara Tomoko、Yoshizawa Takahiro、Dotsu Yosuke、Koyama Junji、Saiki Masafumi、Sonoda Tomoaki、Kitazono Satoru、Yanagitani Noriko、Horiike Atsushi、Inase Naohiko、Kasahara Kazuo、Nishio Makoto、Katayama Ryohei
    • Journal Title

      Lung Cancer

      Volume: 117 Pages: 1-6

    • DOI

      10.1016/j.lungcan.2017.12.018

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed
  • [Journal Article] Recurrent 8q24 rearrangement in blastic plasmacytoid dendritic cell neoplasm: association with immunoblastoid cytomorphology, MYC expression, and drug response.2018

    • Author(s)
      Kana Sakamoto, Ryohei Katayama, Reimi Asaka, Seiji Sakata, Satoko Baba, Hideki Nakasone, Sumie Koike, Naoko Tsuyama, Akito Dobashi, Makoto Sasaki, Ryo Ichinohasama, Emi Takakuwa, Rie Yamazaki, Jun Takizawa, Takahiro Maeda, Miwako Narita, Koji Izutsu, Yoshinobu Kanda, Koichi Ohshima and Kengo Takeuchi
    • Journal Title

      Leukemia

      Volume: 32 Issue: 12 Pages: 2590-2603

    • DOI

      10.1038/s41375-018-0154-5

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer2018

    • Author(s)
      Katayama Ryohei
    • Journal Title

      Cancer Science

      Volume: 109 Issue: 3 Pages: 572-580

    • DOI

      10.1111/cas.13504

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] 3D culture system containing gellan gum restores oncogene dependence in ROS1 rearrangements non-small cell lung cancer.2018

    • Author(s)
      Bo Gong, Tomoko Oh-hara, Naoya Fujita, Ryohei Katayama
    • Journal Title

      Biochem. Biophys. Res. Commun.

      Volume: 501 Issue: 2 Pages: 527-533

    • DOI

      10.1016/j.bbrc.2018.05.031

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] A safety study of newly generated anti-podoplanin-neutralizing antibody in cynomolgus monkey (Macaca fascicularis).2018

    • Author(s)
      Ukaji T, Takemoto A, Katayama R, Takeuchi K, Fujita N
    • Journal Title

      Oncotarget

      Volume: 9 Issue: 70 Pages: 33322-33336

    • DOI

      10.18632/oncotarget.26055

    • Related Report
      2018 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] Morphological changes and their advantages in Bacillus subtilis colonies responding to environmental pH variation.2018

    • Author(s)
      Sohei Tasaki, Maika Nakayama, Wataru Shoji
    • Journal Title

      RIMS Kokyuroku

      Volume: 2087 Issue: 5 Pages: 24-30

    • DOI

      10.1111/dgd.12383

    • NAID

      120006861197

    • Related Report
      2018 Annual Research Report
    • Open Access
  • [Journal Article] 8. Mechanisms of resistance to NTRK inhibitors and therapeutic strategies in NTRK1-rearranged cancers.2017

    • Author(s)
      Miho Jane Fuse, Koutaroh Okada, Tomoko Oh-hara, Hayato Ogura, Naoya Fujita, Ryohei Katayama
    • Journal Title

      Mol Cancer Ther.

      Volume: 16 Issue: 10 Pages: 2130-2143

    • DOI

      10.1158/1535-7163.mct-16-0909

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] TKI-addicted ROS1-rearranged cells are destined to survival or death by the intensity of ROS1 kinase activity2017

    • Author(s)
      Hayato Ogura, Yuka Nagatake-Kobayashi, Jun Adachi, Takeshi Tomonaga, Naoya Fujita, Ryohei Katayama
    • Journal Title

      Sci. Rep.

      Volume: 7 Issue: 1 Pages: 5519-5519

    • DOI

      10.1038/s41598-017-05736-9

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed / Open Access
  • [Journal Article] A critical role of platelet TGF-b release in podoplanin-mediated tumour invasion and metastasis2017

    • Author(s)
      Takemoto A, Okitaka M, Takagi S, Takami M, Sato S, Nishio M, Okumura S, Fujita N
    • Journal Title

      Scientific Reports

      Volume: 7 Issue: 1 Pages: 42186-42186

    • DOI

      10.1038/srep42186

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed / Open Access / Acknowledgement Compliant
  • [Journal Article] Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation2017

    • Author(s)
      Kenichi Miyata, Ai Takemoto, Sakae Okumura, Makoto Nishio, Naoya Fujita
    • Journal Title

      Sci. Rep.

      Volume: 7 Issue: 1 Pages: 4059-4059

    • DOI

      10.1038/s41598-017-04324-1

    • Related Report
      2017 Annual Research Report
    • Peer Reviewed / Open Access
  • [Presentation] Multi-agent modelとphase-fieldモデルによる血管新生シミュレーション2022

    • Author(s)
      米倉 晴紀、中澤 嵩、田崎創平、中井清彦
    • Organizer
      日本応用数理学会第18回研究部会連合発表会
    • Related Report
      2021 Annual Research Report
  • [Presentation] Antitumor drug development and the Japanese Cancer Association2021

    • Author(s)
      藤田直也
    • Organizer
      第80回日本癌学会学術総会
    • Related Report
      2021 Annual Research Report
    • Invited
  • [Presentation] Diverse drug resistance mechanisms and overcoming the resistance by drug repurposing2021

    • Author(s)
      片山量平、藤田直也
    • Organizer
      第80回日本癌学会学術総会
    • Related Report
      2021 Annual Research Report
    • Invited
  • [Presentation] Identification of molecular targets in early-onset colorectal cancers by sequencing and drug screening2021

    • Author(s)
      鈴木麻衣、清水裕貴、丸山航平、大原智子、藤田直也、長山聡、片山量平
    • Organizer
      第80回日本癌学会学術総会
    • Related Report
      2021 Annual Research Report
  • [Presentation] Identification of intrinsic resistance mechanisms to KRAS-G12C specific inhibitor using patient derived colorectal cancer cells2021

    • Author(s)
      丸山航平、清水裕貴、鈴木麻衣、大原智子、藤田直也、長山聡、片山量平
    • Organizer
      第80回日本癌学会学術総会
    • Related Report
      2021 Annual Research Report
  • [Presentation] Osteosarcoma promotes pulmonary metastasis via the release of lysophosphatidic acid from activated platelets2021

    • Author(s)
      高木 聡、小池 清恵、竹本 愛、菅原 稔、藤田 直也、片山 量平
    • Organizer
      第80回日本癌学会学術総会
    • Related Report
      2021 Annual Research Report
  • [Presentation] Discovery of the FLT3 inhibitor gilteritinib as a novel therapeutic strategy to overcome ALK-TKI resistance2021

    • Author(s)
      水田隼斗、竹本愛、高木聡、清水史郎、西尾誠人、藤田直也、片山量平
    • Organizer
      第80回日本癌学会学術総会
    • Related Report
      2021 Annual Research Report
  • [Presentation] Identification of the achilles heels of colorectal cancer cells harboring BRAF V600E mutation by focused inhibitor library screening2021

    • Author(s)
      清水裕貴、丸山航平、鈴木麻衣、大原智子、高橋祐生、長山聡、藤田直也、片山量平
    • Organizer
      第80回日本癌学会学術総会
    • Related Report
      2021 Annual Research Report
  • [Presentation] L747P mutation in EGFR mediates the resistance to gefitinib and allosteric inhibitor by losing αC-helix flexibility2021

    • Author(s)
      大原智子、藤田直也、西尾誠人、片山量平
    • Organizer
      第80回日本癌学会学術総会
    • Related Report
      2021 Annual Research Report
  • [Presentation] ポドプラニン標的薬の治療効果と毒性を評価するためのノックインマウスの作製2021

    • Author(s)
      宇梶太雄、高木聡、藤田直也
    • Organizer
      第30回日本がん転移学会
    • Related Report
      2021 Annual Research Report
  • [Presentation] 活性化血小板由来LPAはLPAR1活性化を介して骨肉腫の肺転移を促進する2021

    • Author(s)
      高木聡、小池清恵、藤田直也、片山量平
    • Organizer
      第25回日本がんがん分子標的治療学会
    • Related Report
      2021 Annual Research Report
  • [Presentation] FLT3阻害薬ギルテリチニブは多剤耐性ALK陽性肺がんの耐性を克服する2021

    • Author(s)
      水田隼斗、高木聡、竹本愛、西尾誠人、藤田直也、清水史郎、片山量平
    • Organizer
      第25回日本がんがん分子標的治療学会
    • Related Report
      2021 Annual Research Report
  • [Presentation] Regulation of cellular diversity in tumor microenvironment by platelet activation-inducing molecule Podoplanin2020

    • Author(s)
      Satoshi Takagi, Ryohei Katayama, Ai Takemoto, Naoya Fujita
    • Organizer
      第43回日本分子生物学会年会
    • Related Report
      2020 Annual Research Report
    • Invited
  • [Presentation] がん臨床検体を用いた免疫チェックポイント阻害薬耐性機構の探索と分泌型PD-L1バリアント2020

    • Author(s)
      片山量平、藤田直也
    • Organizer
      第24回日本がん分子標的治療学会
    • Related Report
      2020 Annual Research Report
    • Invited
  • [Presentation] 分子プロファイルを用いたBRAF V600E変異陽性大腸がんに対する有効な薬剤の発見2020

    • Author(s)
      清水裕貴、丸山航平、瀬戸陽介、キョウ博、大原智子、高橋祐生、長山聡、藤田直也、片山量平
    • Organizer
      第79回日本癌学会学術総会
    • Related Report
      2020 Annual Research Report
  • [Presentation] 薬剤耐性変異予測モデル構築に向けたALK-TKIの薬効評価2020

    • Author(s)
      水田隼斗、大原智子、小池清恵、岩見真吾、清水史郎、藤田直也、片山量平
    • Organizer
      第79回日本癌学会学術総会
    • Related Report
      2020 Annual Research Report
  • [Presentation] 手術検体からのKRAS G12C 変異大腸がん細胞株の樹立と新規併用療法の探索2020

    • Author(s)
      丸山航平、清水裕貴、大原智子、長山聡、藤田直也、片山量平
    • Organizer
      第79回日本癌学会学術総会
    • Related Report
      2020 Annual Research Report
  • [Presentation] 環境変動に対する枯草菌の集団形態2020

    • Author(s)
      田﨑創平
    • Organizer
      第32回さいたま数理解析セミナー
    • Related Report
      2020 Annual Research Report
  • [Presentation] 環境変動に対する枯草菌の集団形態2020

    • Author(s)
      田﨑創平
    • Organizer
      明治非線型数理セミナー・秋の学校
    • Related Report
      2020 Annual Research Report
  • [Presentation] 環境変動に対する枯草菌の集団形態2020

    • Author(s)
      田﨑創平
    • Organizer
      MIMS研究集会「現象と数理モデルー数理モデリング学の形成に向けてー」
    • Related Report
      2020 Annual Research Report
  • [Presentation] Morphologies of Bacillus subtilis communities responding to environmental variation2020

    • Author(s)
      Sohei Tasaki
    • Organizer
      JSPS Core-to-Core Program “Establishing International Research Network of Mathematical Oncology”
    • Related Report
      2020 Annual Research Report
    • Int'l Joint Research / Invited
  • [Presentation] データ同化による多階層生命科学2020

    • Author(s)
      田﨑創平
    • Organizer
      日本数理生物学会2020
    • Related Report
      2020 Annual Research Report
  • [Presentation] A mathematical modeling approach to epigenetic dynamics2020

    • Author(s)
      Sohei Tasaki
    • Organizer
      9th ASHBi Colloquium
    • Related Report
      2020 Annual Research Report
    • Invited
  • [Presentation] A unique ex vivo tumor model: 3D co-cultured system with cancer and stromal cells including blood microvessels.2020

    • Author(s)
      Yuki Takahashi, Kei Tsukamoto, Rii Morimura, Isana Nada, Yuki Shimizu, Ryohei Katayama, Eiji Shinozaki, Satoshi Nagayama, Michiya Matsusaki, Shiro Kitano, Kensei Yamaguchi, Naoya Fujita
    • Organizer
      ASCO-GI 2020
    • Related Report
      2019 Annual Research Report
    • Int'l Joint Research
  • [Presentation] 分泌型PD-L1バリアントを介した免疫チェックポイント治療薬治療耐性機構の発見2019

    • Author(s)
      キョウ博、清谷一馬、坂田征士、西尾誠人、竹内賢吾、河本宏、藤田直也、片山量平
    • Organizer
      第78回日本癌学会学術総会
    • Related Report
      2019 Annual Research Report
    • Invited
  • [Presentation] がんの進化と多様性により生み出される多様な治療抵抗性機構の解析2019

    • Author(s)
      片山量平、キョウ博、西尾誠人、藤田直也
    • Organizer
      第19回日本蛋白質科学会年会・第71回日本細胞生物学会大会 合同年次大会
    • Related Report
      2019 Annual Research Report
    • Invited
  • [Presentation] 肺がんのチロシンキナーゼ阻害薬耐性と免疫チェックポイント阻害薬耐性2019

    • Author(s)
      片山量平、藤田直也
    • Organizer
      第23回日本がん分子標的治療学会
    • Related Report
      2019 Annual Research Report
    • Invited
  • [Presentation] Development of a humanized anti-podoplanin antibody inhibiting tumor-dependent platelet activation.2019

    • Author(s)
      Ai Takemoto, Nobuhiko Gyobu, Mamoru Kakino, Shinya Fujihara, Naoki Goda, Junya Maeda, Miho Takami, Takao Ukaji, Satoshi Takagi, Ryohei Katayama, Kazue Tsuji-Takayama, Kenji Ichihara, Shinobu Nakayama, Yoshiyuki Ohsugi, and Naoya Fujita
    • Organizer
      The 24th ISCC Symposium
    • Related Report
      2019 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Identification of secreted PD-L1 variants as a decoy of PD-L1 blockade antibody mediating the therapeutic resistance.2019

    • Author(s)
      Bo Gong, Kazuma Kiyotani, Seiji Sakata, Ken Takahashi, Seiji Nagano, Shun Kumehara, Satoko Baba, Benjamin Besse, Noriko Yanagitani, Luc Friboulet, Makoto Nishio, Kengo Takeuchi, Hiroshi Kawamoto, Naoya Fujita, and Ryohei Katayama
    • Organizer
      2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    • Related Report
      2019 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Predication of lorlatinib resistance mechanisms and therapeutic strategies to overcome the resistance in ALK rearranged non-small cell lung cancer.2019

    • Author(s)
      Koutaroh Okada, Mitsugu Araki, Tomoko Oh-hara, Makoto Nishio, Yasushi Okuno, Naoya Fujita, Ryohei Katayama
    • Organizer
      2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
    • Related Report
      2019 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Investigation of EMT-mediated anti-cancer drug resistance of cancer cells by single-cell RNA-seq analysis2019

    • Author(s)
      Yosuke Seto, Ryohei Katayama
    • Organizer
      SMBE 2019 “The annual conference of the society for molecular biology and evolution”
    • Related Report
      2019 Annual Research Report
    • Int'l Joint Research
  • [Presentation] ドライバーがん遺伝子の活性化変異が誘導する分子標的薬耐性と新たな脆弱性2019

    • Author(s)
      片山量平、岡田康太郎、藤田直也
    • Organizer
      第42回日本分子生物学会年会
    • Related Report
      2019 Annual Research Report
  • [Presentation] 次世代ROS1/NTRK阻害薬DS-6051bによるCrizotinib耐性の克服2019

    • Author(s)
      片山量平、キョウ博、西尾誠人、藤田直也
    • Organizer
      第78回日本癌学会学術総会
    • Related Report
      2019 Annual Research Report
  • [Presentation] 分泌型PD-L1スプライシングバリアントを介した免疫チェックポイント治療薬耐性機構の発見2019

    • Author(s)
      キョウ博、西尾誠人、藤田直也、片山量平
    • Organizer
      第23回日本がん分子標的治療学会
    • Related Report
      2019 Annual Research Report
  • [Presentation] 血小板活性化因子PDPNを介した腫瘍免疫微小環境の制御2019

    • Author(s)
      高木聡、小池清恵、藤田直也、片山量平
    • Organizer
      第23回日本がん分子標的治療学会
    • Related Report
      2019 Annual Research Report
  • [Presentation] 初回治療オシメルチニブ後に予想される変異蓄積による獲得耐性機構2018

    • Author(s)
      内堀健、北園聡、柳谷典子、堀池篤、西尾誠人、稲瀬直彦、藤田直也、片山量平
    • Organizer
      肺癌学会
    • Related Report
      2018 Annual Research Report
  • [Presentation] KRAS変異大腸がんにおける分子プロファイリングに基づく新規併用治療法の探索2018

    • Author(s)
      キョウ博、清水裕貴、大原智子、長山聡、藤田直也、片山量平
    • Organizer
      第77回 日本癌学会学術総会
    • Related Report
      2018 Annual Research Report
  • [Presentation] BRAF V600E変異陽性大腸がんにおける新たなサブグループの発見2018

    • Author(s)
      清水裕貴、キョウ博、大原智子、長山聡、藤田直也、片山量平
    • Organizer
      第77回 日本癌学会学術総会
    • Related Report
      2018 Annual Research Report
  • [Presentation] がんと血小板の結合を標的とする化合物の探索と解析2018

    • Author(s)
      竹本愛、片山量平、藤田直也
    • Organizer
      第77回 日本癌学会学術総会
    • Related Report
      2018 Annual Research Report
  • [Presentation] Her2 活性化変異陽性肺がん細胞株の樹立とキナーゼ阻害薬の評価2018

    • Author(s)
      大原智子、藤田直也、片山量平
    • Organizer
      第77回 日本癌学会学術総会
    • Related Report
      2018 Annual Research Report
  • [Presentation] オシメルチニブ初回治療のシーケンスで予想される耐性機構としての多重変異について2018

    • Author(s)
      内堀健、西尾誠人、稲瀬直彦、藤田直也、片山量平
    • Organizer
      第16回 日本臨床腫瘍学会学術集会
    • Related Report
      2018 Annual Research Report
  • [Presentation] サルポドプラニンの血小板凝集誘導活性におけるPLAG4ドメインの役割2018

    • Author(s)
      宇梶太雄、竹本愛、藤田直也
    • Organizer
      第27回日本がん転移学会学術集会
    • Related Report
      2018 Annual Research Report
  • [Presentation] がん患者検体を用いた腫瘍組織の統合解析と新薬開発2018

    • Author(s)
      藤田直也
    • Organizer
      理研・生命医科学シンポジウム「新たな生命医科学の融合 ~ゲノム・免疫・疾患システムを究める~」
    • Related Report
      2017 Annual Research Report
    • Invited
  • [Presentation] 1st and 2nd generation ALK-TKI rescues the next-generation ALK-TKI resistance mediated by double mutations2017

    • Author(s)
      Koutaroh Okada, Shigeo Sato, Naoya Fujita, Ryohei Katayama
    • Organizer
      第22回International Symposium on Cancer Chemotherapy
    • Related Report
      2017 Annual Research Report
    • Int'l Joint Research
  • [Presentation] Driver Oncogene陽性肺がんにおける獲得耐性の分子基盤と新たな治療戦略2017

    • Author(s)
      片山量平、藤田直也
    • Organizer
      第76回 日本癌学会学術総会
    • Related Report
      2017 Annual Research Report
    • Invited
  • [Presentation] Resistance mechanisms to NTRK-TKIs in NTRK1 rearranged cancer2017

    • Author(s)
      大原智子、佐藤重夫、藤田直也、片山量平
    • Organizer
      第76回 日本癌学会学術総会
    • Related Report
      2017 Annual Research Report
  • [Presentation] ポドプラニンが誘導する血小板TGF- 放出による転移促進機構2017

    • Author(s)
      竹本愛、藤田直也
    • Organizer
      第26回日本がん転移学会学術集会
    • Related Report
      2017 Annual Research Report
  • [Book] がん微小環境に1細胞レベルで挑む2021

    • Author(s)
      藤田 直也
    • Total Pages
      220
    • Publisher
      羊土社
    • ISBN
      9784758103961
    • Related Report
      2021 Annual Research Report
  • [Remarks] 新学術領域「細胞ダイバース」ホームページ

    • URL

      http://cdiversity.umin.jp/index.html

    • Related Report
      2021 Annual Research Report 2020 Annual Research Report 2019 Annual Research Report
  • [Remarks] ALK融合遺伝子陽性肺がんにおける薬剤耐性がん細胞の新たな治療標的候補を発見

    • URL

      https://www.jfcr.or.jp/chemotherapy/news/9205.html

    • Related Report
      2021 Annual Research Report
  • [Remarks] 肉腫の肺転移機構を解明し、転移阻害薬候補を発見

    • URL

      https://www.jfcr.or.jp/chemotherapy/news/8782.html

    • Related Report
      2021 Annual Research Report
  • [Remarks] スパコンを用いた長時間MDシミュレーションが解き明かす変異型EGFRタンパク質の構造と治療薬感受性

    • URL

      https://www.jfcr.or.jp/chemotherapy/news/8478.html

    • Related Report
      2021 Annual Research Report
  • [Remarks] プレスリリース

    • URL

      https://www.jfcr.or.jp/laboratory/news/8217.html

    • Related Report
      2020 Annual Research Report
  • [Remarks] 【プレスリリース】分泌型PD-L1バリアントを介した免疫チェックポイント阻害薬耐性機序の発見

    • URL

      https://www.jfcr.or.jp/chemotherapy/news/6432.html

    • Related Report
      2019 Annual Research Report
  • [Remarks] 【ニュースリリース】ROS1融合遺伝子陽性肺がんに対する新薬候補化合物DS-6051bの共同研究成果

    • URL

      https://www.jfcr.or.jp/chemotherapy/news/6813.html

    • Related Report
      2019 Annual Research Report
  • [Remarks] 新学術領域「細胞ダイバース」 ホームページ

    • URL

      http://cdiversity.umin.jp/index.html

    • Related Report
      2018 Annual Research Report
  • [Remarks] 公益財団法人がん研究会がん化学療法センター基礎研究部 ホームページ

    • URL

      https://www.jfcr.or.jp/chemotherapy/department/fundamental/index.html

    • Related Report
      2018 Annual Research Report
  • [Remarks] 理研フィジカルバイオロジー研究チーム ホームページ

    • URL

      http://www.qbic.riken.jp/phb/

    • Related Report
      2018 Annual Research Report
  • [Remarks] 新学術領域研究「細胞ダイバース」ホームページ

    • URL

      http://cdiversity.umin.jp/member/fujita.html

    • Related Report
      2017 Annual Research Report
  • [Remarks] 公益財団法人がん研究会 がん化学療法センター基礎研究部のホームページ内

    • URL

      http://www.jfcr.or.jp/chemotherapy/department/fundamental/index.html

    • Related Report
      2017 Annual Research Report

URL: 

Published: 2017-07-04   Modified: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi